[{"id":"1bdd6f63-5019-4415-8262-b36f6b64000b","acronym":"","url":"https://clinicaltrials.gov/study/NCT04592484","created_at":"2021-01-19T20:28:45.384Z","updated_at":"2024-07-02T16:35:56.190Z","phase":"Phase 1/2","brief_title":"A First-in-Human Study of CDK-002 (exoSTING) in Subjects With Advanced/Metastatic, Recurrent, Injectable Solid Tumors","source_id_and_acronym":"NCT04592484","lead_sponsor":"Codiak BioSciences","biomarkers":" PD-L1","pipe":"","alterations":" ","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e exoSTING"],"overall_status":"Completed","enrollment":" Enrollment 27","initiation":"Initiation: 09/15/2020","start_date":" 09/15/2020","primary_txt":" Primary completion: 08/03/2022","primary_completion_date":" 08/03/2022","study_txt":" Completion: 12/23/2022","study_completion_date":" 12/23/2022","last_update_posted":"2023-02-08"}]